+44 (0)1865 595230
0 Items

Respiratory syncytial virus

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States.

 

To support research into RSV infection we offer both recombinant antigens and highly specific monoclonal antibodies.

Respiratory syncytial virus background

Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus. It belongs to the genus Pneumovirus, subfamily Pneumovirinae and is a member of the Paramyxoviridae family of viruses. Human RSV is a widespread virus that causes more than 30 million new cases of RSV infection each year. Two major antigenic groups of human respiratory syncytial virus have been identified, which are classified as subtypes A and B, with additional antigenic variability existing within each subtype. Both A and B subtypes co-circulate but reports suggest that one subtype dominates during an epidemic 1 ( Sullender, WM).

RSV primarily causes lower respiratory tract infection in infants and young children. In many cases, the virus causes a mild respiratory illness but pneumonia and bronchiolitis can develop in children under 2 years of age and in elderly patients. In addition, children with pre-existing heart, lung and neuromuscular diseases can also be at risk of developing severe RSV infection resulting in hospitalisation. In older patients, severe RSV infection may exacerbate pre-existing conditions such as asthma and chronic obstructive pulmonary disease 2 (CDC).

Treatment of severe RSV infection varies but may involve the use of steroids, antibiotics, or antiviral therapy. Monoclonal antibody therapy is available for the prophylactic treatment of specific high-risk cases but treatment is expensive and therefore limited 3 (Turner, TL et al). An effective vaccine for RSV is not currently available but several potential candidates are currently under investigation 4 (WHO).

References

  1. Sullender, WM (2000). Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev. 13:1-15.
  1. Centers for disease control: Respiratory syncytial virus infection (RSV)
  1. Turner, TL et al (2014). Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res.6: 217–225.
  1. WHO Consultation on respiratory syncytial virus (RSV) vaccine development

Respiratory syncytial virus Antigens

In support of IVD assay development and also of vaccine R&D studies, we have prepared recombinant RSV glycoprotein G in our mammalian cell expression system. RSV gG is the major attachment protein of the virus, mediating cellular entry.

Respiratory syncytial virus Antibodies

We are pleased to offer a pair of monoclonal antibodies specific for respiratory syncytial virus, which may be used in the development of immunoassays. These antibodies are highly specific, and do not cross-react with adenovirus or influenza viruses.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

1 + 6 =

Customer Feedback